Altering Cervical Cancer’s Trajectory Mary S. Beattie, MD, MAS Medical Director, Women’s Health...

14
Altering Cervical Cancer’s Trajectory Mary S. Beattie, MD, MAS Medical Director, Women’s Health BioOncology US Medical Affairs

Transcript of Altering Cervical Cancer’s Trajectory Mary S. Beattie, MD, MAS Medical Director, Women’s Health...

Page 1: Altering Cervical Cancer’s Trajectory Mary S. Beattie, MD, MAS Medical Director, Women’s Health BioOncology US Medical Affairs.

Altering Cervical Cancer’s TrajectoryMary S. Beattie, MD, MASMedical Director, Women’s Health BioOncologyUS Medical Affairs

Page 2: Altering Cervical Cancer’s Trajectory Mary S. Beattie, MD, MAS Medical Director, Women’s Health BioOncology US Medical Affairs.

Genentech seeks to take a leadership role, in partnership with other key stakeholders, in the prevention of cervical cancer

2

Y• Screening and treatment provide curative intervention in ~95% of women

• Yet ≥8M women have not been screened within the last 5 years, and nearly 4K die from cervical cancer (CC) annually

• Genentech is focusing on doing what is right for patients, and therefore are committed to reducing the incidence of advanced CC

Y

1. Data Challenges/Competitions and Open Innovation

• Host data challenge to identify segments most at risk to not be screened so interventions can be better targeted in the future

• Leverage open innovation to bring together a diverse group and cultivate innovative approaches/products

2. Multidisciplinary Stakeholder Summit

• Execute summit with diverse stakeholders to develop initiatives that address provider barriers

3. Community Based Education Programs

• Conduct situational analysis of existing free screening programs and community infrastructure

• Initiative a scalable pilot to increase education and utilization of programs

4. Point-of-Care Education

• Deploy PCP in-office education program to link screening to CC prevention in partnership with the CDC

• Assess impact of program on screening rates

Context

Ongoing Pilot Programs

Page 3: Altering Cervical Cancer’s Trajectory Mary S. Beattie, MD, MAS Medical Director, Women’s Health BioOncology US Medical Affairs.

33

Objectives and Agenda

Objectives:•Appreciate cervical cancer (CC) burden•Understand why cervical cancer is a model disease for screening•Emphasize importance of cervical cancer screening, including potential missed opportunities and barriers

Agenda•Cervical cancer background and epidemiology•HPV, CC natural history, prevention, and screening

Page 4: Altering Cervical Cancer’s Trajectory Mary S. Beattie, MD, MAS Medical Director, Women’s Health BioOncology US Medical Affairs.

Cervical cancer is the third most common cancer in women worldwide1,2

4

In 2008, 530,000 new cases occurred globally, resulting in 275,000 deaths

1.GLOBOCAN 2008. International Agency for Research on Cancer website. http://globocan.iarc.fr/ as of 5/132.Schiffman M, Castle PE. N Engl J Med 2005; 353:2101-2104

* Numbers indicate cases per 100,000 population

Page 5: Altering Cervical Cancer’s Trajectory Mary S. Beattie, MD, MAS Medical Director, Women’s Health BioOncology US Medical Affairs.

Cervical cancer epidemiology: US

5

12,360 new cases in 2014 (1.5% of all new diagnoses in women)

4020 deaths in 2014 (1.5% of all cancer deaths in women)

Relatively rare in US21st most common cancer

Two-thirds of cases occur in women ≤54 years

Median age at diagnosis: 49 years

Tends to develop in younger women

Minority women have highest incidence and mortality rates

African-American

American Indian/Alaska Native

Hispanic/Latino

Increased Pap test usage has contributed to a 70% decrease in cervical cancer incidence since the 1950s

Perc

en

t of

New

C

ase

s

Age

Page 6: Altering Cervical Cancer’s Trajectory Mary S. Beattie, MD, MAS Medical Director, Women’s Health BioOncology US Medical Affairs.

66

HPV, necessary but not sufficient

• Human Papilloma Virus infection is common• Over 75% of sexually active adults (by 50 y/o) have been exposed to HPV1

• Other potentially important predictors for cervical cancer are smoking and immunosupression

• Cervical cancer - model disease for which prevention and screening can have significant impact• Cervical cancer characteristics

Generally slow growth and progression Opportunities for intervention in pre-cancer

• Prevention – HPV vaccine • Screening – Pap smears

1. Manhart LE et al. Sex Transm Dis 2006; 33(8) 502-508

Page 7: Altering Cervical Cancer’s Trajectory Mary S. Beattie, MD, MAS Medical Director, Women’s Health BioOncology US Medical Affairs.

Progression to cervical cancer

• Normal cells of the cervix gradually develop precancerous changes that can eventually evolve into cancer

• Precancerous changes can be detected with the Pap test

• Treating dysplasia can prevent most cervical cancers

7

Page 8: Altering Cervical Cancer’s Trajectory Mary S. Beattie, MD, MAS Medical Director, Women’s Health BioOncology US Medical Affairs.

88

Natural history of high-risk HPV infection and potential progression to cervical cancer1

1. Reprinted from Pagliusi SR, Aguado Mt. Vaccine, 2004;23:569-578. Copyright©2004, with permission from Elsevier

* Cervical squamous intraepithelial neoplasia

* *

Page 9: Altering Cervical Cancer’s Trajectory Mary S. Beattie, MD, MAS Medical Director, Women’s Health BioOncology US Medical Affairs.

Screening guidelines – generally agreed points

• Pap screening should generally be started at 21 years old and performed every 3 years until age of 65

• HPV co-testing, when used, should begin at 30 years old and should be performed every 5 years until age 65

• All screening can be stopped in women after the age of 65, provided they have an adequate screening history

• Women who have had a hysterectomy with removal of cervix do not need to have cervical screening, unless the hysterectomy was done to treat a precancerous cervical lesion or cervical cancer

9References:American Cancer Society (ACS), American Society of Colposcopy and Cervical Pathology (ASCPP), and the American Society for Clinical Pathology (ASCP)The US Preventive Services Task Force (USPSTF)The American College of Obstetricians and Gynecologists (ACOG)

Page 10: Altering Cervical Cancer’s Trajectory Mary S. Beattie, MD, MAS Medical Director, Women’s Health BioOncology US Medical Affairs.

System failures are associated with Cervical Cancer in the US • Most CC cases are in women who didn’t get screening in the prior 3

years• Most of these “fail to screen” had more than 3 visits to health care

providers in the prior 3 years

10References:

Page 11: Altering Cervical Cancer’s Trajectory Mary S. Beattie, MD, MAS Medical Director, Women’s Health BioOncology US Medical Affairs.

However, cervical screening may not detect all abnormalities

• Because screening may not detect all abnormalities, it does not always ensure early intervention1,2

• False-negative caused by sampling and detection errors1

• Adenocarcinoma difficult to detect by Pap smear2

• Some women with cervical cancer have had a recent normal Pap smear prior to diagnosis3

• Some women are nonadherent to cervical cancer screening3

111. Nanda K, McCrory DC, Myers ER, et al. Ann Intern Med. 2000;132:810-819.2. Johnston G, MacIsaac M, Rankin E. Available at: http://cancercare.ns.ca/media/documents/surveillance_info_system.pdf. Accessed February 4, 20053. Sung HY, Kearney KA, Miller M, Kinney W, Sawaya GF, Hiatt RA. Cancer. 2000;88:2283-2289

Page 12: Altering Cervical Cancer’s Trajectory Mary S. Beattie, MD, MAS Medical Director, Women’s Health BioOncology US Medical Affairs.

Summary

• Cervical cancer is largely preventable• Screening barriers and missed opportunities deserve further study• Eventually, research in this field could potentially lead to impactful

interventions• “It takes a village”

12

Page 13: Altering Cervical Cancer’s Trajectory Mary S. Beattie, MD, MAS Medical Director, Women’s Health BioOncology US Medical Affairs.

Appendix

13

Page 14: Altering Cervical Cancer’s Trajectory Mary S. Beattie, MD, MAS Medical Director, Women’s Health BioOncology US Medical Affairs.

Classification of cervical cancer by failures in screening, detection and follow-up1

141. Leyden WA, Manos M, Geiger AM, et al. J Natl Cancer Inst. 2005;97:675-683. Reprinted with permission from Oxford Journals, Oxford University Press